Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
- 4 September 2009
- journal article
- review article
- Published by Wiley in Brain Pathology
- Vol. 19 (4), 674-693
- https://doi.org/10.1111/j.1750-3639.2009.00315.x
Abstract
Despite aggressive multimodal treatment approaches, the prognosis for patients with diffuse gliomas remains disappointing. Glioma cells often extensively infiltrate in the surrounding brain parenchyma, a phenomenon that helps them to escape surgical removal, radiation exposure and chemotherapy. Moreover, conventional therapy is often associated with considerable local and systemic side effects. Therefore, the development of novel therapeutic approaches is essential to improve the outcome of these patients. Immunotherapy offers the opportunity to specifically target residual radio—and chemoresistant tumor cells without damaging healthy neighboring brain tissue. Significant progress has been made in recent years both in understanding the mechanisms of immune regulation in the central nervous system (CNS) as well as tumor‐induced and host‐mediated immunosuppression elicited by gliomas. In this review, after discussing the special requirements needed for the initiation and control of immune responses in the CNS, we focus on immunological phenomena observed in glioma patients, discuss different immunological approaches to attack glioma‐associated target structures and touch on further strategies to improve the efficacy of immunotherapy of gliomas.Keywords
This publication has 104 references indexed in Scilit:
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Dendritic cell vaccination and immune monitoringCancer Immunology, Immunotherapy, 2008
- Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant gliomaSeminars in Immunology, 2008
- Selective cancer-germline gene expression in pediatric brain tumorsJournal of Neuro-Oncology, 2008
- Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migrationCancer Immunology, Immunotherapy, 2008
- Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brainCancer Immunology, Immunotherapy, 2008
- Th17: the third member of the effector T cell trilogyCurrent Opinion in Immunology, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006